Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Docetaxel 33Prednisone 28enzalutamide 19Abiraterone Acetate 13pembrolizumab 11gallium 68 PSMA-11 9Leuprolide 9Radiotherapy 8Pluvicto 8Magnetic Resonance Spectroscopy 8Nivolumab 7Estramustine 7abiraterone 6Radiotherapy, Intensity-Modulated 6Goserelin 6Carboplatin 6Biopsy 6olaparib 5cemiplimab 5bicalutamide 5Specimen Handling 5Paclitaxel 5Cyclophosphamide 5temsirolimus 4orteronel 4darolutamide 4cabazitaxel 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Sirolimus 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms × MLN 8237 × Clear all
NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Thomas Jefferson University

Phase 1/2 Completed
9 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡